Aio­los Bio launch­es with $245M Se­ries A, chas­ing one of asth­ma’s hottest tar­gets

Two Genen­tech vets have land­ed one of biotech’s largest Se­ries A rounds of 2023 as they launch Aio­los Bio to ad­vance an asth­ma drug in-li­censed from Chi­na.

Aio­los Bio on Tues­day an­nounced a $245 mil­lion round, which ranks as one of the in­dus­try’s largest Se­ries A rais­es in 2023. The start­up ex­pects to be­gin a Phase II asth­ma study next year for its sole drug can­di­date, an an­ti-TSLP an­ti­body.

Aio­los CEO Khurem Fa­rooq and fel­low co-founder An­tho­ny Adamis pre­vi­ous­ly worked side-by-side at Genen­tech, re­spec­tive­ly over­see­ing the com­mer­cial and de­vel­op­ment teams for the biotech’s im­munol­o­gy and oph­thal­mol­o­gy work. Fa­rooq most re­cent­ly ran Gy­ro­scope Ther­a­peu­tics, which No­var­tis agreed to ac­quire in De­cem­ber 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER